Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GSK2126458
DRUG
2 trials
Sponsors
GlaxoSmithKline
Conditions
Idiopathic Pulmonary Fibrosis
Solid Tumours
Phase 1
Dose-Escalation Study of GSK2126458
Completed
NCT00972686
GlaxoSmithKline
Solid Tumours
Start: 2009-08-31
End: 2015-03-31
Updated: 2017-05-09
A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Completed
NCT01725139
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Start: 2013-03-08
End: 2016-07-12
Updated: 2019-11-21
Related Papers
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
European Respiratory Journal
2019-02-14
139 citations
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Thorax
2016-04-21
199 citations